Adveritas (ASX:AV1) clocks A$16.3m ARR and the SME funnel turns real
Adveritas (ASX:AV1) lifted ARR to A$16.3 million and its SME self-serve platform is converting organically…
- ASX: EBR
EBR Systems
Share Price and News
ASX BIG FOUR - LIVE SNAPSHOT
SELL
Whitehaven Coal
(ASX:WHC)
Paul Flynn
01/03/2026
$8.7m
BUY
Elixir Energy
(ASX:EXR)
Featured
SELL
Aspen Group
(ASX:APZ)
David Dixon
03/03/2026
$11.4m
BUY
Lovisa
(ASX:LOV)
Brett Blundy
04/03/2026
$6.8m
— Company Overview
About EBR Systems
EBR Systems is a med-tech stock focused on heart diseases. The company’s flagship innovation, the EBR’s WiSE system (Wireless Stimulation Endocardially) CRT System, is the world’s first and only leadless left ventricular endocardial pacing device. It stimulates the heart, delivering it when the heart slows, becomes irregular, or when the two ventricles become unsynchronised – and yes, it can detect when this happens. WiSE is the size of a coked grain of rice – 5% the size of a conventional pacemaker – because it has no battery in the heart. This technology addresses the limitations of traditional CRT by eliminating the need for leads and wires, thereby reducing complications associated with lead placement and longevity. Lead or wires can be an impediment for some to have cardiac systems for a variety of reasons. The system’s design allows for compatibility with a range of existing pacing devices, enhancing its versatility in clinical applications. WiSE has been shown to improve patients’ clinical status and reduce heart failure hospitalisations and mortality.
EBR's Company History
EBR Systems was established in 2003 with a mission to develop innovative therapies for cardiac rhythm diseases – specifically a wireless method of stimulating the heart. In 2011, the company initiated its first human clinical trial for the WiSE CRT System. By 2015, EBR achieved the first regulatory approval – CE Mark Approval. In 2018, it accomplished the world’s first totally leadless CRT implant and it initiated a pivotal clinical trial to get FDA approval. The U.S. FDA granted the WiSE System Breakthrough Device Designation in 2019, recognising its potential to offer more effective treatment options for patients with heart failure. And so a clinical trial ensured and it was a complete success. The Phase 3 trial, completed in early 2023, there was a significant improvement in heart function compared to the benchmark – as measured by a 16.4% reduction in left ventricular end systolic volume compared to 9.3% for the benchmark. WiSE also saw 80.9% safety vs 70% for the benchmark. In April 2025, EBR received FDA approval for the WiSE CRT System, marking a significant milestone in the company’s history.
- Free Report
Get Our Full ASX Stock Analysis Report
Expert buy ranges, stop losses and detailed fundamentals for 200+ ASX stocks – free every week.
— Forward View
Future Outlook of EBR Systems (ASX: EBR)
The FDA approval of the WiSE CRT System positions EBR Systems for substantial growth in the American cardiac rhythm management market. At this stage it is only approved for adult patients indicated for cardiac resynchronisation therapy (CRT), have an existing implanted right ventricular pacing system and either have had previous unsuccessful implantations or who have had pacemakers where a standard upgrade is not advised due to the risks. This market is at least US$3.6bn, but the worldwide market is US$13.6bn. A limited market release occurred in 2025 amongst sites where the company has existing relationships with Key Opinion Leaders. A stronger push for sales growth will come in 2026, once the company has expanded its sales team. EBR completed a follow-on equity offering, raising $50m in September 2025, providing the company with additional capital to support its commercialisation efforts and further clinical studies. This capital infusion is expected to aid in expanding market adoption of the WiSE CRT System and exploring new indications for its technology. The most recent commercial update came in January 2026 when it reported US$870-935k revenue for Q4 of 2025 and US$1,552-1,617k for the entire year. The company also commenced a clinical trial with WiSE, a study using it alongside a leadless pacemaker to achieve totally leadless CRT. This market is 3 times larger than the existing market (i.e. these patients are 75% of the market).
— Our Assessment
Is EBR a Good Stock to Buy?
EBR Systems presents a compelling investment opportunity for those interested a medtech that is just rolling out a product into the market. The company’s WiSE CRT System addresses a significant unmet need in heart failure treatment, offering a less invasive and potentially more effective alternative to traditional CRT devices. The company is at a pivotal point with its commercial rollout, and there is potential for rapid sales growth. Success in the current Leadless CRT trial could expand the market significantly. However, investors should be mindful of the company’s current lack of profitability and the risks associated with commercialising new medical technologies. Trump’s tariffs may impact the company – if in no other way, causing share price volatility.
— Our Stock Analysis
Related Articles
Appen’s (ASX:APX) post-Google turnaround has finally showed up!
Appen (ASX:APX) has given FY26 revenue guidance of US$270m to US$300m as the AI data…
ASX Data Centre Beneficiaries: If You Missed NextDC & SKS, These 5 Stocks Could Be Next To Soar...
ASX Data Centre Stocks, either pureplays or companies any kind of direct or indirect exposure,…
Nvidia’s $81.6bn Quarter: 4 ASX Stocks Riding the AI Infrastructure Boom
ASX Stocks Riding the AI Infrastructure Boom
NVIDIA (NASDAQ: NVDA) is the company that makes…
Vection (ASX:VR1) books A$1.1m as Defence Programme hits A$30.6m
Vection Technologies (ASX:VR1) books A$1.1m in fresh defence and Algho AI orders, lifting its cumulative…
SanDisk (NASDAQ:SNDK) The Sell Case Behind a 3,300% AI Memory Rally
Why we think Sandisk is a downgrade rating to a sell
What if SanDisk is…
— Faq
Frequently Asked Questions
What does EBR Systems do?
EBR Systems manufactures and sells the WiSE CRT System. EBR’s WiSE system (Wireless Stimulation Endocardially) uses wireless technology to deliver pacing stimulation directly to the inside of the left ventricle of the heart, thus preventing heart failure.
How does EBR compare to its peers in the medical device industry?
There are no comparable competitors as it is the only leadless device to deliver CRT (i.e. it does not use leads or wires). Lead or wires can be an impediment for some to have cardiac systems for a variety of reasons.
What is the long-term growth potential for EBR Systems?
The FDA’s scope of approval for the WiSE CRT System is a market of at least US$3.6bn. But the worldwide Cardiac Rhythm Management Market is worth US$13.6bn – $4.8bn of which is pacing, $4bn of which is defibrillation and $4.7bn is CRT.
Is EBR Systems a suitable investment for income-focused investors?
Given that EBR does not currently pay dividends and is focused on growth and reinvestment, it may not align with the objectives of income-focused investors seeking regular dividend payouts.
How does EBR's WiSE CRT system work?
It delivers pacing stimulation directly to the inside of the left ventricle of the heart, thus preventing heart failure. This stimulation is delivered when the heart slows, becomes irregular, or when the two ventricles become unsynchronised – and yes, it can detect when this happens.
Stay Sharp on the ASX
Weekly research. Independent analysis. No noise.
Free forever · Unsubscribe anytime
